An MRI-derived definition of MCI-to-AD conversion for long-term, automatic prognosis of MCI patients

Yaman Aksu1, David J Miller, George Kesidis

  • 1Center for NMR Research, Department of Radiology, Penn State University College of Medicine, Hershey, Pennsylvania, United States of America.

Plos One
|October 25, 2011
PubMed

Insights

This study introduces a novel method to predict Alzheimer's disease (AD) progression in mild cognitive impairment (MCI) patients using brain scans. The new approach improves prognostic accuracy and identifies key brain regions associated with disease progression.

Area of Science:

  • Neuroimaging
  • Neurology
  • Artificial Intelligence

Background:

  • Alzheimer's disease (AD) and mild cognitive impairment (MCI) are significant research areas.
  • Current methods for defining MCI conversion to AD lack consensus and may overlook crucial physiological changes.
  • Existing definitions often ignore rich phenotypic information from brain scans and labeled AD/Control data.

Purpose of the Study:

  • To develop an accurate, automated method for prognosticating MCI conversion to AD using only baseline brain imaging.
  • To propose an innovative definition of MCI conversion based on classifier predictions.
  • To identify reliable brain region biomarkers for predicting AD progression.

Main Methods:

  • Utilized a baseline Control-AD classifier to define MCI converters.
  • Bootstrapped a second classifier trained to predict MCI conversion based on the first classifier's output.
  • Leveraged data from the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Main Results:

  • The proposed definition significantly improved prognostic accuracy compared to traditional CDR-based conversion.
  • Identified MCI subpopulations with higher consistency with known AD biomarkers, including CSF markers.
  • Pinpointed key brain regions that serve as prognostic biomarkers for AD.

Conclusions:

  • The novel definition of MCI conversion using classifier predictions offers superior prognostic accuracy.
  • This approach effectively integrates imaging and clinical data for better AD progression prediction.
  • The identified brain region biomarkers hold potential for early detection and monitoring of AD.